Lundbeck begins phase II trial of antibody for migraine prevention

Antibody treatment Lu AG09222 will be tested in a phase II trial including around 230 patients, the company reports. The candidate uses a different mechanism than the relatively new class of CGRP receptors, which have been gaining ground on the migraine market.
Photo: Jens Dresling
Photo: Jens Dresling
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN

A few days after receiving pivotal European approval for its migraine drug Vyepti, Lundbeck is moving ahead with another candidate for the treatment of migraines.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading